As of 2024-12-12, the EV/EBITDA ratio of Hansa Biopharma AB (HNSA.ST) is -3.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HNSA.ST's latest enterprise value is 2,475.33 mil SEK. HNSA.ST's TTM EBITDA according to its financial statements is -626.45 mil SEK. Dividing these 2 quantities gives us the above HNSA.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.3x | 15.8x |
| Forward P/E multiples | 16.0x - 18.4x | 17.2x |
| Fair Price | (153.78) - (166.16) | (158.40) |
| Upside | -603.9% - -644.4% | -619.0% |
| Date | EV/EBITDA |
| 2024-11-29 | -4.17 |
| 2024-11-28 | -4.17 |
| 2024-11-27 | -4.00 |
| 2024-11-26 | -4.00 |
| 2024-11-25 | -4.06 |
| 2024-11-22 | -3.97 |
| 2024-11-21 | -3.88 |
| 2024-11-20 | -3.96 |
| 2024-11-19 | -3.89 |
| 2024-11-18 | -3.88 |
| 2024-11-15 | -4.08 |
| 2024-11-14 | -4.22 |
| 2024-11-13 | -4.17 |
| 2024-11-12 | -3.92 |
| 2024-11-11 | -4.05 |
| 2024-11-08 | -4.21 |
| 2024-11-07 | -4.26 |
| 2024-11-06 | -4.15 |
| 2024-11-05 | -4.28 |
| 2024-11-04 | -4.44 |
| 2024-11-01 | -4.62 |
| 2024-10-31 | -4.58 |
| 2024-10-30 | -4.71 |
| 2024-10-29 | -4.75 |
| 2024-10-28 | -4.82 |
| 2024-10-25 | -4.84 |
| 2024-10-24 | -4.93 |
| 2024-10-23 | -4.95 |
| 2024-10-22 | -4.95 |
| 2024-10-21 | -5.04 |
| 2024-10-18 | -5.03 |
| 2024-10-17 | -5.12 |
| 2024-10-16 | -4.99 |
| 2024-10-15 | -5.07 |
| 2024-10-14 | -5.08 |
| 2024-10-11 | -5.15 |
| 2024-10-10 | -5.09 |
| 2024-10-09 | -5.39 |
| 2024-10-08 | -5.39 |
| 2024-10-07 | -5.63 |
| 2024-10-04 | -4.99 |
| 2024-10-03 | -4.87 |
| 2024-10-02 | -4.98 |
| 2024-10-01 | -4.93 |
| 2024-09-30 | -4.98 |
| 2024-09-27 | -5.06 |
| 2024-09-26 | -4.94 |
| 2024-09-25 | -4.98 |
| 2024-09-24 | -4.99 |
| 2024-09-23 | -5.05 |